Spain has become one of Europe’s strongest clinical trial markets.
With a population of 47 million and 930 trials authorized in 2024, Spain offers sponsors a rare combination of scale, speed and research depth.
Its advantage is not only regulatory. Spain has a highly active hospital ecosystem across Barcelona, Madrid, Valencia, Seville, Bilbao and Salamanca, supported by strong public healthcare infrastructure and experienced investigator networks.
Oncology remains Spain’s clearest strength, with major research centers such as Vall d’Hebron, VHIO, Hospital Clínic de Barcelona, Gregorio Marañón and other leading academic sites supporting high volume clinical development.
For sponsors, Spain is not just a useful European market. It is a foundational market for programs that need fast startup, strong site performance, oncology leadership, demographic breadth and credible Western European execution.